[Form 4] Skywest Inc Insider Trading Activity

Rhea-AI Filing Summary

On 07/29/2025 Immunome, Inc. (IMNM) granted President & CEO Clay B. Siegall a stock option for 800,000 common shares at an exercise price of $10.60, expiring 07/28/2035. No shares were bought or sold; the filing reflects only an incentive award.

The option vests over four years: 25% on 07/29/2026 and the remaining 75% in equal monthly installments (1/36) thereafter. Following the grant, Siegall beneficially owns 800,000 derivative securities and retains no change in non-derivative share ownership. The transaction was reported on a single-person Form 4 and was not made under a 10b5-1 plan.

This award strengthens management equity alignment but represents potential dilution if exercised. No other financial metrics, sales, or purchases were disclosed in the filing.

Positive

• Large option grant ties CEO compensation directly to long-term share price performance, aligning interests with shareholders.

Negative

• Potential dilution of roughly 2–3% of outstanding shares if the 800,000 options are fully exercised.

Insights

Securities Analyst

TL;DR: Large option grant aligns CEO to value creation; limited immediate impact on float or valuation.

The 800k-share option equals roughly four years of typical executive equity compensation and signals the board’s confidence in Dr. Siegall’s leadership. At a $10.60 strike, incentives are out-of-the-money if shares trade lower, limiting near-term dilution. Investors should factor in potential dilution of ~2.5% of current basic shares if fully exercised, but vesting and a 10-year term spread that effect over time. No insider selling occurred, which is modestly reassuring. Overall impact is neutral to slightly positive.

Corporate Governance Expert

TL;DR: Grant structure follows best-practice four-year vest; no 10b5-1 plan attached.

The award uses a standard 25% one-year cliff plus monthly vesting thereafter, promoting retention through 2029. Absence of a 10b5-1 designation means sales discretion remains with the insider, which can draw governance scrutiny later. Strike price equals the market close on grant date (implied), mitigating back-dating risk. Board transparency is adequate; impact on governance score is neutral.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Woodward Eric

(Last) (First) (Middle)

444 S RIVER ROAD

(Street)

ST. GEORGE UT 84790

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
SKYWEST INC [ SKYW ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CHIEF ACCOUNTING OFFICER

3. Date of Earliest Transaction (Month/Day/Year)
07/29/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/29/2025		S		5,305	D	$116.4744(1)	49,505	D
Common Stock	07/29/2025		S		1,695	D	$117.2992(2)	47,810	D
Common Stock								3,166	I	By 401K Plan

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $116.13 and $117.12. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

2. Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $117.13 and $117.49. Detailed information on the exact number of shares sold at each sale price can be obtained from the issuer upon request.

	/s/ Eric J. Woodward	07/31/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many Immunome (IMNM) shares can the CEO now purchase under the new option grant?

The Form 4 shows an option for 800,000 common shares at a $10.60 strike price.

What is the vesting schedule for the IMNM CEO's 2025 stock options?

25% vests on 07/29/2026; the remaining 75% vests in equal monthly installments over 36 months.

Did the Immunome CEO sell any shares in this filing?

No. The Form 4 reports only an option grant; no shares were bought or sold.

When do the new Immunome options expire?

The options expire on 07/28/2035, giving a 10-year exercise window.

How might this option grant affect future share dilution for IMNM investors?

If fully exercised, the 800,000 shares represent an estimated ~2–3% increase in basic shares outstanding.